Use of probiotics in patients with Parkinson's disease: the importance of the gut-brain axis and dietotherapy – a literature review




Parkinson's disease; Probiotics; Microbiota; Neuroimmunomodulation; Dietotherapy.


Parkinson's disease (PD) is the second most common degenerative disease of the central nervous system affecting between 1 and 2 people in 1,000 and its prevalence increases with age, affecting about 1% of the population over 60 years. Studies in the bidirectional communication between the brain and the intestine have shown that changes in the intestinal microbiota can potentially play an important role in PD and have reported gastrointestinal symptoms (constipation, dysphagia, hypersalivation and swallowing disorders). Current evidence suggests that the health and composition of the intestinal microbiome are due to the effect of diet and the use of probiotics. This study aimed to evaluate the use of probiotics and nutritional therapy for PD. The literature search was performed using the PICoS criterion to extract evidence of relevant studies from articles published in PubMed, ScienceDirect, and MEDLINE, selecting only articles with randomized clinical studies and reviews. Even with a limited number of quality studies in humans, we found research that highlighted the importance of using probiotics and diet in patients with PD, as it brings benefits to gastrointestinal motility, contributes to the symbiosis of GIT and improves stool consistency. It is concluded that the use of probiotics is a good intervention method for patients with PD. Future research should focus on the gut-brain axis and investigate how microbial populations exert pathogenic effects, as well as their interaction with diets and medications.


Agarwal, P., Wang, Y., Buchman, A. S., Holland, T. M., Bennett, D. A., & Morris, M. C. (2018). MIND Diet Associated with Reduced Incidence and Delayed Progression of Parkinsonism in Old Age. Journal of Nutrition, Health and Aging, 22(10), 1211–1215.

Arentsen, T., Qian, Y., Gkotzis, S., Femenia, T., Wang, T., Udekwu, K., Forssberg, H., & Diaz Heijtz, R. (2017). The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior. Molecular psychiatry, 22(2), 257–266.

Baars, A., Oosting, A., Lohuis, M., Koehorst, M., El Aidy, S., Hugenholtz, F., Fransen, F. (2018). Sex differences in lipid metabolism are affected by presence of the gut microbiota. Scientific Reports, 8(1), 1–11.

Barboza, J. L., Okun, M. S., & Moshiree, B. (2015, November 2). The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinsons disease. Expert Opinion on Pharmacotherapy. Taylor and Francis Ltd.

Barichella, M., Pacchetti, C., Bolliri, C., Cassani, E., Iorio, L., Pusani, C., Cereda, E. (2016). Probiotics and prebiotic fiber for constipation associated with Parkinson disease. Neurology, 87(12), 1274–1280.

Bercik, P., Denou, E., Collins, J., Jackson, W., Lu, J., Jury, J., Collins, S. M. (2011). The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology, 141(2).

Borzabadi, S., Oryan, S., Eidi, A., Aghadavod, E., Kakhaki, R. D., Tamtaji, O. R., Asemi, Z. (2018). The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Archives of Iranian Medicine, 21(7), 289–295. https://doi: 10.1080/07315724.2017.1347074

Burgos, R., Bretón, I., Cereda, E., Desport, J. C., Dziewas, R., Genton, L., Bischoff, S. C. (2018). ESPEN guideline clinical nutrition in neurology. Clinical Nutrition, 37(1), 354–396.

Cassani, E., Privitera, G., Pezzoli, G., Pusani, C., Madio, C., Iorio, L., & Barichella, M. (2011). Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterologica e Dietologica, 57(2), 117–121. Retrieved from

Chen, R. C., Chang, S. F., Su, C. L., Chen, T. H. H., Yen, M. F., Wu, H. M., Liou, H. H. (2001). Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan County, Taiwan. Neurology, 57(9), 1679–1686.

Chenoll, E., Casinos, B., Bataller, E., Astals, P., Echevarría, J., Iglesias, J. R., Genovés, S. (2011). Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Applied and Environmental Microbiology, 77(4), 1335–1343.

Chung, H.-J., Sim, J.-H., Min, T.-S., & Choi, H.-K. (2018). Metabolomics and Lipidomics Approaches in the Science of Probiotics: A Review. Journal of Medicinal Food, 21(11), 1086–1095.

Comi, C., & Tondo, G. (2017, January 1). Insights into the protective role of immunity in neurodegenerative disease. Neural Regeneration Research. Editorial Board of Neural Regeneration Research.

Cryan, J. F., O’Riordan, K. J., Sandhu, K., Peterson, V., & Dinan, T. G. (2020, February 1). The gut microbiome in neurological disorders. The Lancet Neurology. Lancet Publishing Group.

Cussotto, S., Sandhu, K. V., Dinan, T. G., & Cryan, J. F. (2018, October 1). The Neuroendocrinology of the Microbiota-Gut-Brain Axis: A Behavioural Perspective. Frontiers in Neuroendocrinology. Academic Press Inc.

Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019, August 1). The role of short-chain fatty acids in microbiota–gut–brain communication. Nature Reviews Gastroenterology and Hepatology. Nature Publishing Group.

Del Tredici, K., Rüb, U., Vos, R. A. I. De, Bohl, J. R. E., & Braak, H. (2002). Where Does Parkinson Disease Pathology Begin in the Brain? Journal of Neuropathology and Experimental Neurology, 61(5).

Dinan, T. G., & Cryan, J. F. (2017, March 1). The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterology Clinics of North America. W.B. Saunders.

Dutta, S. K., Verma, S., Jain, V., Surapaneni, B. K., Vinayek, R., Phillips, L., & Nair, P. P. (2019). Parkinson’s disease: The emerging role of gut dysbiosis, antibiotics, probiotics, and fecal microbiota transplantation. Journal of Neurogastroenterology and Motility. Korean Society of Neurogastroenterology and Motility.

Fang, X. (2019, January 1). Microbial treatment: the potential application for Parkinson’s disease. Neurological Sciences. Springer-Verlag Italia s.r.l.

Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015, June 1). Gastrointestinal dysfunction in Parkinson’s disease. The Lancet Neurology. Lancet Publishing Group.

Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Keshavarzian, A. (2011). Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS ONE, 6(12).

Franzosa, E. A., Huang, K., Meadow, J. F., Gevers, D., Lemon, K. P., Bohannan, B. J. M., & Huttenhower, C. (2015). Identifying personal microbiomes using metagenomic codes. Proceedings of the National Academy of Sciences of the United States of America, 112(22), E2930–E2938.

Fülling, C., Dinan, T. G., & Cryan, J. F. (2019, March 20). Gut Microbe to Brain Signaling: What Happens in Vagus…. Neuron. Cell Press.

Gao, K., Pi, Y., Mu, C., Farzi, A., Liu, Z., & Zhu, W. (2019). Increasing carbohydrate availability in the hindgut promotes hypothalamic neurotransmitter synthesis: aromatic amino acids linking the microbiota–brain axis. Journal of Neurochemistry, 149(5), 641–659.

Gazerani, P. (2019, September 1). Probiotics for Parkinson’s disease. International Journal of Molecular Sciences. MDPI AG.

Georgescu, D., Ancusa, O., Georgescu, L., Ionita, I., & Reisz, D. (2016). Nonmotor gastrointestinal disorders in older patients with Parkinson's disease: is there hope? Clinical Interventions in Aging, Volume 11, 1601–1608.

Ghaisas, S., Maher, J., & Kanthasamy, A. (n.d.). Gut microbiome in health and disease: linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases.

Ghaisas, S., Maher, J., & Kanthasamy, A. (2016, February 1). Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacology and Therapeutics. Elsevier Inc.

Girolamo, F., Coppola, C., & Ribatti, D. (2017). Immunoregulatory effect of mast cells influenced by microbes in neurodegenerative diseases. Brain, Behavior, and Immunity, 65, 68–89.

Goodrich, J. K., Davenport, E. R., Waters, J. L., Clark, A. G., & Ley, R. E. (2016, April 29). Cross-species comparisons of host genetic associations with the microbiome. Science. American Association for the Advancement of Science.

Gomes, P. C., & Maynard, D. da C. (2020). Relação entre o hábito alimentar, consumo de probiótico e prebiótico no perfil da microbiota intestinal: Revisão integrativa. Research, Society and Development, 9(8), e718986101.

Grzeskowiak, L., Collado, M. C., Mangani, C., Maleta, K., Laitinen, K., Ashorn, P., Salminen, S. (2012). Distinct Gut microbiota in southeastern African and northern European infants. Journal of Pediatric Gastroenterology and Nutrition, 54(6), 812–816.

Hiller, A. L., Murchison, C. F., Lobb, B. M., O’Connor, S., O’Connor, M., & Quinn, J. F. (2018). A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson’s disease: Does age matter? PLoS ONE, 13(9).

Holzer, P., Farzi, A., Hassan, A. M., Zenz, G., Jacan, A., & Reichmann, F. (2017, November 22). Visceral inflammation and immune activation stress the brain. Frontiers in Immunology. Frontiers Media S.A.

Kalampokini, S., Becker, A., Fassbender, K., Lyros, E., & Unger, M. (2019). Nonpharmacological Modulation of Chronic Inflammation in Parkinson’s Disease: Role of Diet Interventions. Parkinson’s Disease, 2019.

Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Shannon, K. M. (2015). Colonic bacterial composition in Parkinson’s disease. Movement Disorders, 30(10), 1351–1360.

Kim, N., Yun, M., Oh, Y. J., & Choi, H. J. (2018, March 1). Mind-altering with the gut: Modulation of the gut-brain axis with probiotics. Journal of Microbiology. Microbiological Society of Korea.

Kouli, A., Torsney, K. M., & Kuan, W.-L. (2018). Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In Parkinson’s Disease: Pathogenesis and Clinical Aspects (pp.3–26). Codon Publications.

Kraeuter, A. K., Phillips, R., & Sarnyai, Z. (2020, July 13). Ketogenic therapy in neurodegenerative and psychiatric disorders: From mice to men. Progress in Neuro-Psychopharmacology and Biological Psychiatry. Elsevier Inc.

Kujawska, M., & Jodynis-Liebert, J. (2018, November 12). What is the evidence that parkinson’s disease is a prion disorder, which originates in the gut? International Journal of Molecular Sciences. MDPI AG.

Lange, K. W., Nakamura, Y., Chen, N., Guo, J., Kanaya, S., Lange, K. M., & Li, S. (2019, June 1). Diet and medical foods in Parkinson’s disease. Food Science and Human Wellness. Elsevier B.V.

Lin, C. H., Chen, C. C., Chiang, H. L., Liou, J. M., Chang, C. M., Lu, T. P., Wu, M. S. (2019). Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease. Journal of Neuroinflammation, 16(1).

Liu, D., Ke, Z., & Luo, J. (2017, September 1). Thiamine Deficiency and Neurodegeneration: the Interplay Among Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy. Molecular Neurobiology. Humana Press Inc.

Liu, Y., & Zhang, B. S. (2014). Serum 25-hydroxyvitamin D predicts severity in Parkinson’s disease patients. Neurological Sciences, 35(1), 67–71.

Lombardi, V. C., De Meirleir, K. L., Subramanian, K., Nourani, S. M., Dagda, R. K., Delaney, S. L., & Palotás, A. (2018, November 1). Nutritional modulation of the intestinal microbiota: future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease. Journal of Nutritional Biochemistry. Elsevier Inc.

Marietta, E., Horwath, I., & Taneja, V. (2018, January 1). Microbiome, Immunomodulation, and the Neuronal System. Neurotherapeutics. Springer New York LLC.

Martin, C. R., Osadchiy, V., Kalani, A., & Mayer, E. A. (2018, January 1). The Brain-Gut-Microbiome Axis. CMGH. Elsevier Inc.

McCarty, M. F., & Lerner, A. (2020). Nutraceuticals Targeting Generation and Oxidant Activity of Peroxynitrite May Aid Prevention and Control of Parkinson’s Disease. International Journal of Molecular Sciences, 21(10), 3624.

Mertsalmi, T. H., Aho, V. T. E., Pereira, P. A. B., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2017). More than constipation – bowel symptoms in Parkinson’s disease and their connection to gut microbiota. European Journal of Neurology, 24(11), 1375–1383.

Minato, T., Maeda, T., Fujisawa, Y., Tsuji, H., Nomoto, K., Ohno, K., & Hirayama, M. (2017). Progression of Parkinson’s disease is associated with gut dysbiosis: Two-year follow-up study. PLoS ONE, 12(11).

Mozaffari, S., Nikfar, S., Daniali, M., & Abdollahi, M. (2020, April 12). The pharmacological management of constipation in patients with Parkinson’s disease: a much-needed relief. Expert Opinion on Pharmacotherapy. Taylor and Francis Ltd.

Mukherjee, A., Biswas, A., & Das, S. K. (2016, July 7). Gut dysfunction in Parkinson’s disease. World Journal of Gastroenterology. Baishideng Publishing Group Co., Limited.

Noyce, A. J., Bestwick, J. P., Silveira-Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012, December). Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology. Ann Neurol.

Olanow, C. W., Klein, C., & Schapira, A. H. V. (2020). Parkinson’s Disease | Harrison’s Principles of Internal Medicine| AccessMedicine | McGraw-Hill Medical. Retrieved June 21, 2020. Retrieved from

Parashar, A., & Udayabanu, M. (2017, May 1). Gut microbiota: Implications in Parkinson’s disease. Parkinsonism and Related Disorders. Elsevier Ltd.

Parkinson, J. (2002). An Essay on the Shaking Palsy. J Neuropsychiatry Clin Neurosci (Vol. 14).

Pascale, A., Marchesi, N., Govoni, S., & Barbieri, A. (2020, July 1). Targeting the microbiota in pharmacology of psychiatric disorders. Pharmacological Research. Academic Press.

Perez-Pardo, P., Dodiya, H. B., Broersen, L. M., Douna, H., van Wijk, N., Lopes da Silva, S., Kraneveld, A. D. (2018). Gut–brain and brain–gut axis in Parkinson’s disease models: Effects of a uridine and fish oil diet. Nutritional Neuroscience, 21(6), 391–402.

Petticrew, M., & Roberts, H. (2006). M. Petticrew and H. Roberts. Systematic Reviews in the Social Sciences: A Practical Guide. Counselling and Psychotherapy Research, 6(4), 304–305.

Phillips, M. C. L., Murtagh, D. K. J., Gilbertson, L. J., Asztely, F. J. S., & Lynch, C. D. P. (2018). Low-fat versus ketogenic diet in Parkinson’s disease: A pilot randomized controlled trial. Movement Disorders, 33(8), 1306–1314.

Pierantozzi, M., Pietroiusti, A., Sancesario, G., Lunardi, G., Fedele, E., Giacomini, P., Stanzione, P. (2001). Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson’s disease patients. In Neurological Sciences (Vol. 22, pp. 89–91). Neurol Sci.

Quigley, E. M. M. (2017, December 1). Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Current Neurology and Neuroscience Reports. Current Medicine Group LLC 1.

Rimmelzwaan, L. M., Van Schoor, N. M., Lips, P., Berendse, H. W., & Eekhoff, E. M. W. (2016, March 30). Systematic Review of the Relationship between Vitamin D and Parkinson’s Disease. Journal of Parkinson’s Disease. IOS Press.

Sánchez, B., Delgado, S., Blanco-Míguez, A., Lourenço, A., Gueimonde, M., & Margolles, A. (2017). Probiotics, gut microbiota, and their influence on host health and disease. Molecular Nutrition & Food Research, 61(1), 1600240.

Santos, S. F., De Oliveira, H. L., Yamada, E. S., Neves, B. C., & Pereira, A. (2019, June 4). The gut and Parkinson’s disease - A bidirectional pathway. Frontiers in Neurology. Frontiers Media S.A.

Sasmita, A. O. (2019). Modification of the gut microbiome to combat neurodegeneration. Reviews in the Neurosciences, 30(8).

Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Auvinen, P. (2015). Gut microbiota are related to Parkinson’s disease and clinical phenotype. Movement Disorders, 30(3), 350–358.

Shen, L. (2015). Associations between B Vitamins and Parkinson’s Disease. Nutrients, 7(9), 7197–7208.

Soto, M., Herzog, C., Pacheco, J. A., Fujisaka, S., Bullock, K., Clish, C. B., & Kahn, C. R. (2018). Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism. Molecular Psychiatry, 23(12), 2287–2301.

Spielman, L. J., Gibson, D. L., & Klegeris, A. (2018, November 1). Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases. Neurochemistry International. Elsevier Ltd.

Sureda, A., del Mar Bibiloni, M., Julibert, A., Bouzas, C., Argelich, E., Llompart, I., … Tur, J. A. (2018). Adherence to the mediterranean diet and inflammatory markers. Nutrients, 10(1).

Tamtaji, O. R., Taghizadeh, M., Daneshvar Kakhaki, R., Kouchaki, E., Bahmani, F., Borzabadi, S., Asemi, Z. (2019). Clinical and metabolic response to probiotic administration in people with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition, 38(3), 1031–1035.

Tysnes, O. B., & Storstein, A. (2017, August 1). Epidemiology of Parkinson’s disease. Journal of Neural Transmission. Springer-Verlag Wien.

Uyar, G. Ö., & Yildiran, H. (2019). A nutritional approach to microbiota in Parkinson’s disease. Bioscience of Microbiota, Food and Health. BMFH Press.

Vernocchi, P., Del Chierico, F., & Putignani, L. (2016, July 26). Gut microbiota profiling: Metabolomics based approach to unravel compounds affecting human health. Frontiers in Microbiology. Frontiers Media S.A.

Westfall, S., Lomis, N., Kahouli, I., Dia, S. Y., Singh, S. P., & Prakash, S. (2017, October 1). Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. Cellular and Molecular Life Sciences. Birkhauser Verlag AG.

WHO, & FAO. (2001). Probiotics in food Health and nutritional properties and guidelines for evaluation FAO FOOD AND NUTRITION PAPER. Probiotics in Food, 2. Retrieved from

Yarandi, S. S., Peterson, D. A., Treisman, G. J., Moran, T. H., & Pasricha, P. J. (2016, April 1). Modulatory effects of gut microbiota on the central nervous system: How gut could play a role in neuropsychiatric health and diseases. Journal of Neurogastroenterology and Motility. Journal of Neurogastroenterology and Motility.

Zwickey, H., Lipski, L., Wu, W., Kong, Q., Tian, P., Zhai, Q., Kunugi, H. (2018). Nutritional modulation of the intestinal microbiota: future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease. Journal of Nutritional Biochemistry, 19(3), 1–16.



How to Cite

Santos , R. B. ., Anjos, H. A. dos ., Ribeiro , T. T. ., & Correia , V. D. D. M. R. . (2020). Use of probiotics in patients with Parkinson’s disease: the importance of the gut-brain axis and dietotherapy – a literature review. Research, Society and Development, 9(9), e357997259.



Health Sciences